Ro.co vs IVIM Health: Oral Wegovy vs Compounded GLP-1 Options
Ro.co vs IVIM Health is primarily a choice between an FDA-approved oral GLP-1 option and a clinician-guided compounded program. Early verdict: choose Ro.co if you prioritize access to the FDA-approved Wegovy pill and an injection-free, branded medication path; choose IVIM Health if you prefer a clinician-guided compounded program with strong third-party ratings and a structured GLP-1 ID protocol.
Side-by-side: medication type, pricing, protocol, and reviews
This comparison focuses on the most distinctive differences supported by the sources: medication formulation and regulatory status, entry and ongoing pricing signals, proprietary protocols and study claims, and third-party satisfaction ratings. Below, Ro.co and IVIM Health are compared directly across these topics.
1. Medication formulation and regulatory status
Ro.co: Ro is the only platform in this comparison offering access to the Wegovy pill, described as the first and only FDA-approved oral GLP-1 weight loss medication. The source emphasizes that Ro prescribes FDA-approved finished medication rather than compounded products and notes that treatment is available only when a licensed clinician determines it is medically appropriate. The provider also states compounded medications, when offered elsewhere, are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
IVIM Health: IVIM prescribes compounded semaglutide and tirzepatide formulations. The source explicitly states these are compounded medications and are not FDA-approved. IVIM notes compounded drugs have not undergone FDA review for safety, effectiveness, or quality and are prepared by independent, licensed compounding pharmacies. Both providers include the regulatory qualifier that compounded drugs lack FDA review.
See IVIM Health program details
2. Pricing and entry cost
Ro.co: The captured Ro evidence states you can “Get Started Online for Just $39.” It also notes that ongoing branded medication pricing varies and that branded FDA-approved medications can cost significantly more than compounded alternatives. Ro says it does not charge hidden fees and discloses pricing before you complete your consultation.
IVIM Health: IVIM’s published details highlight a $99 first month promotion and ongoing pricing at $174/month in typical messaging, while another captured page shows $75/mo for compounded semaglutide and $133/mo for tirzepatide plus a $74.99/mo program fee. IVIM also promotes a free month membership with code GIFT75 and a no-obligation free consultation valued at $75 for new patients. These figures are presented with the qualifier that RX is required after clinical evaluation.
3. Protocols, claims, and evidence
Ro.co: The source emphasizes access to an FDA-approved oral option as Ro’s distinguishing clinical claim. Ro positions this as meaningful for patients who are injection-averse because it removes the needle barrier. Ro notes its prescribed products are FDA-evaluated finished products rather than compounded medications.
IVIM Health: IVIM highlights a proprietary GLP-1 ID protocol claiming up to 40% faster weight loss, described in the source as a proprietary claim and not an independent clinical trial result. IVIM also cites peer-reviewed retrospective observational studies in Obesity Pillars that support clinical outcomes across branded and compounded formulations and clarifies these are not randomized head-to-head trials. IVIM frames its protocol as clinician-guided titration and optimization rather than a fixed-dose plan.
Learn about Ro.co’s Wegovy pill option
4. Third-party ratings and patient satisfaction
Ro.co: The captured Ro pages emphasize brand trust and being an established full-service telehealth platform. Specific third-party rating figures are not supplied for Ro in the captured evidence.
IVIM Health: IVIM is singled out for an unusually strong satisfaction signal: a 4.9-star rating on both Google and Trustpilot, described as rare dual third-party verification in this market. The source positions this dual rating as a key reason patients might choose IVIM when weighting provider choices by independent reviews.
Comparison table
| Criteria | Ro.co | IVIM Health |
|---|---|---|
| Medication formulation | Wegovy pill, FDA-approved finished medication | Compounded semaglutide or tirzepatide (not FDA-approved) |
| Starting cost | Get started online for just $39 | Promotions show $99 first month; captured pages list $75/mo or $99 first month |
| Ongoing pricing signal | Ongoing branded medication pricing varies and can be high | $174/month ongoing typical messaging; other captured pricing shows $75/$133 plus program fee |
| Protocol/claims | Focus on FDA-approved oral option and brand trust | Proprietary GLP-1 ID protocol claiming up to 40% faster results; based on IVIM’s own data |
| Third-party ratings | Established platform; specific ratings not supplied | 4.9 stars on Google and Trustpilot per source |
What the sources do not supply
The captured evidence does not supply comprehensive head-to-head clinical trial data comparing Ro.co’s Wegovy pill to IVIM’s compounded protocols, nor does it supply complete ongoing price lists for all medications at either provider. Where study claims appear, each source includes qualifiers about study design or proprietary status; follow-up with the provider is required for details not supplied here.
Conclusion: Choose based on regulatory preference, cost priorities, and ratings
Ro.co vs IVIM Health boils down to priorities. If regulatory status and an injection-free FDA-approved oral option matter most, Ro.co offers access to the Wegovy pill and a $39 online start. If independent third-party ratings and a clinician-guided proprietary protocol are your deciding factors, IVIM Health presents a clinician-optimized GLP-1 ID program with 4.9-star Google and Trustpilot ratings and promotional entry options.
Choose Ro.co if you prioritize access to an FDA-approved oral GLP-1 and prefer a branded, finished medication path. Choose IVIM Health if you value dual 4.9-star third-party ratings, a structured GLP-1 ID protocol, and compounded medication options under clinician supervision.